BioCentury
ARTICLE | Strategy

RNAi(ndependence)

July 16, 2007 7:00 AM UTC

Last week's deal between RNAi company Alnylam Pharmaceuticals Inc. and Roche will provide a big bolus of non-dilutive financing that ALNY will put to two uses: moving its pipeline through the clinic and working on the drug delivery technologies required to deliver RNAi therapeutics.

The deal thus gives Alnylam leverage to add value in the near term through clinical proof of concept and to solve technical issues in the delivery of its molecules...